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Background  and  objectives:  Acetylcholinesterase  inhibitors  may  cause  postoperative  residual
curarization when  they  are  used  for  reversal  of  neuromuscular  blockade.  Sugammadex  reverses
neuromuscular  blockade  by  chemical  encapsulation  and  is  not  associated  with  the  side  effects
that  may  occur  with  the  use  of  anticholinesterase  agents.  Because  of  increased  outpatient
surgical  procedures  postoperative  residual  curarization  and  rapid  postoperative  recovery  have
a  greater  importance  in  the  pediatric  patient  population.  The  aim  of  this  study  was  to  compare
the  efﬁcacy  of  sugammadex  and  neostigmine  on  reversing  neuromuscular  blockade  in  pediatric
patients  undergoing  outpatient  surgical  procedures.
Methods:  80  patients,  aged  2--12  years,  scheduled  for  outpatient  surgery  were  enrolled  in  this
randomized prospective  study.  Neuromuscular  blockade  was  achieved  with  0.6  mg  kg−1 rocuro-
nium  and  monitorized  with  train-of-four.  Group  RN  (n  =  40)  received  0.03  mg  kg−1 neostigmine,
Group  RS  (n  =  40)  received  2  mg  kg−1 sugammadex  for  reversal  of  rocuronium.  Extubation  time
(time  from  the  reversal  of  neuromuscular  blockade  to  extubation),  train-of-four  ratio  during
this  time,  time  to  reach  train-of-four  >  0.9,  and  probable  complications  were  recorded.
Results:  There  was  no  signiﬁcant  difference  between  the  patients’  characteristics.  Extuba-
tion time  and  time  to  reach  train-of-four  >  0.9  were  signiﬁcantly  higher  in  Group  RN  (p  =  0.001,
p  =  0.002).  Train-of-four  at  the  time  of  neostigmine/sugammadex  injection  in  Group  RN  were  sig-
niﬁcantly  higher  than  in  the  RS  group  (p  =  0.020).  Extubation  train-of-four  ratio  was  signiﬁcantly
lower  in  Group  RN  (p  =  0.002).
Conclusion:  Sugammadex  provides  safer  extubation  with  a  shorter  recovery  time  than  neostig-
mine in  pediatric  patients  undergoing  outpatient  surgical  procedures.a  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  © 2014  Sociedade  Brasileir∗ Corresponding author.
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Sugammadex  versus  neostigmina  em  pacientes  pediátricos:  Estudo  prospectivo  e
randomizado
Resumo
Justiﬁcativa  e  objetivos:  Os  inibidores  da  acetilcolinesterase  podem  causar  curarizac¸ão  resid-
ual no  pós-operatório  quando  usados  para  reverter  o  bloqueio  neuromuscular.  Sugamadex
reverte  o  bloqueio  neuromuscular  por  encapsulac¸ão  química  e  não  está  associado  aos  efeitos
colaterais  que  podem  ocorrer  com  o  uso  de  agentes  anticolinesterase.  Devido  ao  aumento
dos procedimentos  cirúrgicos  ambulatoriais.  A  curarizac¸ão  residual  e  a  rápida  recuperac¸ão  no
pós-operatório  são  muito  importantes  para  a  populac¸ão  de  pacientes  pediátricos.  O  objetivo
deste  estudo  foi  comparar  a  eﬁcácia  de  sugamadex  e  neostigmina  na  reversão  do  bloqueio
neuromuscular  em  pacientes  pediátricos  submetidos  a  procedimentos  cirúrgicos  ambulatoriais.
Métodos:  80  pacientes,  com  idades  entre  2-12  anos,  programados  para  cirurgias  ambulatoriais
foram incluídos  neste  estudo  prospectivo  e  randomizado.  O  bloqueio  neuromuscular  foi  obtido
com  0,6  mg  kg−1 de  rocurônio  e  monitorizado  com  a  interpretac¸ão  da  sequência  de  quatro  estí-
mulos.  O  Grupo  RN  (n  =  40)  recebeu  0,03  mg  kg−1 de  neostigmina  e  o  Grupo  RS  (n  =  40)  recebeu
2  mg  kg−1 de  sugamadex  para  a  reversão  de  rocurônio.  O  tempo  de  extubac¸ão  (tempo  desde
a  reversão  do  bloqueio  neuromuscular  até  a  extubac¸ão),  a  razão  da  sequência  de  quatro  estí-
mulos  durante  esse  tempo,  o  tempo  para  atingir  uma  sequência  de  quatro  estímulos  >  0,9  e  as
complicac¸ões  prováveis  foram  registrados.
Resultados: Não  houve  diferenc¸a signiﬁcativa  entre  as  características  dos  pacientes.  Os  tempos
de extubac¸ão  e  para  atingir  uma  sequência  de  quatro  estímulos  >  0,9  foram  signiﬁcativamente
maiores no  Grupo  RN  (p  =  0,001,  p  =  0,002).  A  sequência  de  quatro  estímulos  no  momento  da
injec¸ão  de  neostigmina/sugamadex  foi  signiﬁcativamente  maior  no  Grupo  RN  que  no  Grupo  RS
(p  =  0,020).  A  razão  entre  extubac¸ão  e  sequência  de  quatro  estímulos  foi  signiﬁcativamente
menor no  Grupo  RN  (p  =  0,002).
Conclusão:  Sugamadex  proporciona  extubac¸ão  mais  segura  com  um  tempo  de  recuperac¸ão  mais
curto que  o  de  neostigmina  em  pacientes  pediátricos  submetidos  a  procedimentos  cirúrgicos
ambulatoriais.

















ologists (ASA)  physical  status  I,  2--12  years  of  age  who  were
scheduled to  undergo  outpatient  surgery  as  elective  lower
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Postoperative  residual  curarization  (PORC)  in  postoperative
patients is  a  succession  of  the  presence  of  blocked  nicotinic
receptors.1,2 Even  in  observationally  asymptomatic  patients,
60--70% of  these  receptors  can  be  still  blocked.1 PORC  can
cause delayed  recovery,  hypoxia,  metabolic  derangement
and rarely  death.2
Cholinesterase  inhibitors  are  traditionally  used  for  rever-
sal of  neuromuscular  blockade  (NMB).  Among  these  agents
neostigmine is  the  most  potent  and  selective  one.3 It  should
be kept  in  mind  that  cholinesterase  inhibitor  agents  have
multi-systemic side  effects.  Since  these  agents  are  not
selective to  nicotinic  receptors  and  also  stimulate  the  mus-
carinic system,  there  can  be  quite  a  few  serious  adverse
effects as  follows:  Bradycardia,  QT  lengthening,  bron-
choconstriction, hypersalivation  and  increased  motility.3 To
avoid these  effects,  concomitant  anticholinergic  agents,
such as  atropine  or  glikopirolat,  are  administered  to
the patient  before  the  cholinesterase  inhibitors.3 Today,
sugammadex is  an  alternative  to  the  decurarization  proce-
dure, which  was  traditionally  executed  with  cholinesterase
inhibitors. PORC  and  the  muscarinic  side  effects  are  not
anticipated when  using  sugammadex,  which  has  been  devel-
oped so  as  to  be  selective  for  rocuronium  and  vecuronium.4--6
a
sThe  rudimentary  neuromuscular  junction,  the  variability
f ﬁbrin  ﬁbers,  the  differences  in  drug  distribution  and  body
olume in  children  change  their  neuromuscular  conduction.
hese factors  can  cause  prolonged  recovery  and  increased
isk of  PORC.7,8
Sugammadex  is  proved  to  be  a  safe  and  superior  agent
n NMB  reversal  compared  to  neostigmine  in  adults.4--6 How-
ver, there  is  only  one  study  in  the  literature  concerning
ugammadex administration  in  pediatric  patients.9 The  aim
f this  study  was  to  compare  the  efﬁcacy  of  sugammadex  and
eostigmine on  reversing  NMB  in  pediatric  patients  undergo-
ng outpatient  surgical  procedures.
ethods
fter  approval  by  the  local  ethics  committee  and  writ-
en informed  consent  was  obtained  from  the  person  legally
esponsible for  the  child,  this  prospective,  randomized,
ouble-blind, controlled  study  of  pediatric  patients  was
erformed. Eighty  children,  American  Society  of  Anesthesi-bdominal or  urogenital  procedures,  were  included  in  this
tudy.
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Table  1  Age,  mean  time  of  surgery  and  anesthesia.
Variable  Group  RN  (n  =  40)  Group  RS  (n  =  40)  p  value
Age  5.07  ±  3.24  6.48  ±  2.81  0.065
Surgery duration  (min)  60.37  ±  43.71  (43)  63.52  ±  39.78  (49.5)  0.341
Anesthesia duration  (min)  85.50  ±  47.49  (70)  71.77  ±  40.80  (59.5)  0.108
Table  2  Evaluation  of  time  variations.
Group  RN  (n  =  40)  Group  RS  (n  =  40)  p  value
Last  NMB  administration-reversing  time  (min) 44.45 ±  22.17 40.05  ±  23.29 0.390
Last NMB  administration-extubation  time  (min) 47.70 ±  22.05 41.55  ±  23.37 0.230



































































Ga p < 0.05 (mean ± SD).
Any  patients  with  known  drug  hypersensitivity,  kidney
ailure, liver  failure,  diseases  affecting  the  neuromuscular
unction, or  a  history  of  malign  hyperthermia,  and  those
entally retarded,  were  not  included  in  the  study.
All  patients  were  applied  0.5  mg  kg−1 oral  midazolam
0--45 min  before  surgery.  Electrocardiogram  (EKG),  mean
rterial pressure  (MAP),  oxygen  saturation  (SPO2),  heart
ate and  EtCO2 (End-Tidal  CO2)  (Draeger  Primus,  Draeger
edical, Drammen,  Norway)  were  all  monitored  in  the  oper-
ting room.  The  train-of-four  (TOF)  equipment  working  with
he nerve-muscle  acceleromyometry  principle  (TOF  Watch,
rganon Technica,  Eppelheim,  Germany)  was  placed  on  the
lnar nerve  trace  and  transducer  thumbs  of  all  the  patients,
nd the  peripheral  heat  sensor  was  placed  into  the  palmar
ide of  the  hand.
Vascular  access  was  provided  on  the  other  arm,  where
euromuscular monitoring  was  not  applied.  General  anes-
hesia was  induced  in  both  groups  with  5--7  mg  kg−1
hiopental,  1  g  kg−1 fentanyl  and  0.6  mg  kg−1 rocuronium.
0 s  after  the  ﬁrst  dose  of  rocuronium  the  patients  were  oro-
racheally intubated.  The  ﬁrst  TOF  ratio  was  100%  calibrated
nd measured.  Maintenance  of  anesthesia  was  provided  with
% sevoﬂurane  and  50%  O2--50%  N2O.  During  the  operation
OF was  not  measured.
The  effect  of  the  neuromuscular  blocker  was  evaluated
linically according  to  the  increase  of  respiration  frequency,
isruption to  respiration  curve,  and  the  onset  of  muscu-
ar movements.  When  necessary  0.2  mg  kg−1 rocuronium
as administered,  and  the  time  of  the  last  NMB  dose  was
ecorded.
At the  end  of  surgery,  sevoﬂurane  inhalation  was  inter-
upted and  switched  to  100%  O2.  TOF  monitorization  began.
he children  were  randomly  assigned  to  one  of  two  groups
y a  computer-generated  table  of  random  numbers.  When
2 reappeared,  Group  RN  (n  =  40)  received  0.01  mg  kg−1
tropine  and  0.03  mg  kg−1 neostigmine  and  Group  RS  (n  =  40)
eceived 2  mg  kg−1 sugammadex  for  the  reversal  of  the  NMB.
Injection  time  of  neostigmine  or  sugammadex  after  the
ast NMB  and  the  TOF  ratio  at  injection  were  recorded.
atients were  clinically  assessed  for  NMB  recovery  (50%
f normal  tidal  volume,  eye  opening  and  movement)
nd extubated.  Duration  from  NMB  reversal  to  extubation
as evaluated  as  the  extubation  time.  The  TOF  ratio  at
l
hxtubation  and  the  time  to  reach  TOF  >  0.90  were  recorded.
peration and  anesthesia  duration  (time  interval  between
nduction and  interruption  of  sevoﬂurane  inhalation)  were
lso  recorded.  Adverse  effects  such  as  bradycardia,  tachy-
ardia, QT  lengthening,  hypotension,  nausea,  vomiting,
ronchoconstriction, hypersalivation,  diplopia,  rash,  fever,
r  dysgeusia  were  noted.
tatistical  analysis
n  this  study,  statistical  analyses  were  performed  with  NCSS
Number Cruncher  Statistical  System)  2007  and  PASS  2008
tatistical Software  (Utah,  USA)  program.  For  evaluation  of
btained data,  along  with  descriptive  statistical  methods
mean, standard  deviation),  an  independent  samples  test
as used  for  the  comparison  of  quantitative  data,  and  the
ann--Whitney U test  was  used  for  a comparison  of  abnor-
al distribution  parameters  between  two  groups.  Results
ere considered  statistically  signiﬁcant  when  the  p  value
as under  0.05.
esults
ighty  patients  aged  2--12  years,  who  underwent  lower
bdominal or  urogenital  surgery,  completed  this  study
nd were  included  in  one  of  the  two  groups.  Mean  age
as 5.73  ±  3.11  years.  There  was  no  signiﬁcant  difference
etween the  groups  in  age,  time  of  surgery  or  time  of  anes-
hesia (Table  1).
Time  for  applying  neostigmine  or  sugammadex  after  the
ast NMB  and  time  from  the  last  NMB  to  extubation  were
imilar in  both  groups  (Table  2).
Extubation  time  in  Group  RN  was  statistically  higher  than
hat in  Group  RS  (p  =  0.001)  (Fig.  1).
TOF rate  at  the  time  of  neostigmine  or  sugammadex
njection in  Group  RN  was  signiﬁcantly  higher  than  that  in
roup RS  (p  =  0.020)  (Table  3).
TOF  rate  of  Group  RN  at  extubation  was  signiﬁcantlyower compared  to  Group  RS  (p  =  0.002)  (Table  3;  Fig.  2).
The time  when  TOF  rate  exceeded  0.90  was  signiﬁcantly
igher in  the  RN  Group  (p  =  0.002)  (Table  3;  Fig.  3).
No side  effects  occurred  in  both  of  the  groups.
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Table  3  TOF  ratio  evaluation.
Group  RN  (n  =  40)  Group  RS  (n  =  40)  p  value
TOF  ratio  before  reversing 47.25 ±  38.52  (43.5) 28.62  ±  27.58  (23.5)  0.020a
TOF  ratio  at  extubation  76.95  ±  31.0  96.35  ±  21.34  0.002a
Time  to  reach  TOF  ratio  >0.90  (min)  1.97  ±  2.14  (1)  0.46  ±  0.70  (0)  0.002a













Figure  1  Mean  extubation  time  difference  between  groups.




























































et al.,25 11%  of  patients  in  the  neostigmine  group  reachedFigure  3  Mean  time  to  reach  TOF  ratio  >0.90  (min).
Discussion
NMB  agents  are  still  indispensable  for  surgical  procedures
requiring general  anesthesia.  Unfortunately  applications
of NMB  agents  entail  complications,  which  can  lead  to
increased mortality,  such  as  PORC,  airway  obstruction,  aspi-
ration and  hypoxia.  Therefore,  complete  and  rapid  reversal
of NMB  must  be  ensured  at  the  end  of  surgery.1,2,10
NMB  have  a  different  efﬁcacy  in  adults  and  children.  NMB
disperse in  the  extracellular  area.  Because  the  extracellular
area is  relatively  larger  in  children  than  in  adults,  the  neu-
romuscular blockers  create  lower  plasma  concentrations  in
children. Higher  doses  of  NMB  may  be  necessary  to  reach  the
same NMB  level  in  children,  as  in  adults.7,8 The  neuromuscu-
lar junction  in  infants  is  not  sufﬁciently  mature.  Therefore,
the ion  channels  remain  open  for  a  longer  time  and  the  mus-
cles can  easily  be  depolarized.  Moreover,  the  receptors  have
a lower  afﬁnity  for  the  non-depolarizing  agents.7,8 Because
a child’s  diaphragm  has  more  type  I  ﬁbrins  than  an  adult’s,
the diaphragm  is  more  vulnerable  to  NMB  than  the  periph-
eral muscles.  All  these  factors  lead  to  an  increased  risk  of
t
s
aost-operative  apnea  in  pediatric  patients.11 At  this  point
n NMB  reversing  agent  with  a  reduced  PORC  risk  is  of  great
mportance.8,9
Vuksanaj  et  al.12 investigated  the  pharmacokinetic  prop-
rties of  rocuronium  in  children.  They  stated  that  higher
oses of  rocuronium  may  be  necessary  in  children  for
apid onset  of  effect  and  rapid  recovery.  It  has  been
scertained that  NMB  reverses  in  a  shorter  time  with
ocuronium.12,13 Therefore,  we  preferred  to  use  rocuronium
n our  study.
PORC is  one  of  the  feared  complications  after  anesthe-
ia. Acceleromyography  is  the  only  recommended  objective
ethod for  detection  of  residual  block.1,14,15 Unless  the  TOF
atio is  ≥0.9,  normal  vital  muscle  functions  and  spontaneous
espiration are  not  safe.2,14,15 TOF  monitoring  was  impor-
ant in  this  study  to  provide  an  objective  assessment  and
herefore accepted  cut-off  value  was  TOF  ratio  >0.9.
Sugammadex  has  created  a  new  approach  to  the  rapid
eversal of  NMB.  In  comparative  studies,  it  has  been  shown
hat sugammadex  is  more  effective  than  cholinesterase
nhibitors in  the  reversal  of  NMB  when  rocuronium  or  vecuro-
ium was  administered.16,17 Jones  et  al.18 found  that  the
ime to  reach  0.90  TOF  ratio  was  18  times  shorter  with  sug-
mmadex than  with  neostigmine  in  routine  reversal  of  deep
MB. Plaud  mentioned  that  in  his  study  sugammadex  was  10
imes faster  in  efﬁciency.19
Sorgenfrei  et  al.  compared  different  doses  of  sugam-
adex (0.5,  1,  2,  3,  4  mg  kg−1) with  a placebo  administration
n male  patients,  aged  18--64  years.  They  analyzed  the
edian time  necessary  to  reach  TOF  0.90  ratio  after  admin-
stration of  sugammadex  and  found  that  with  every  dose  of
ugammadex the  time  to  reach  0.90  TOF  ratio  shortened.
hen they  compared  the  different  sugammadex  doses,
hey observed  that  the  time  to  reach  0.90  TOF  ratio  was
igniﬁcantly shorter  with  sugammadex  doses  ≥2  mg  kg−1.20
ther  studies  showed  that  ≥2  mg  kg−1 sugammadex  doses
re efﬁcient.21,22 Debaene  et  al.23 reported  that  a  TOF  mea-
urement for  the  depth  of  NMB  is  important  in  deciding  the
ppropriate sugammadex  dose.  Therefore,  we  administered
 mg  kg−1 sugammadex,  and  measured  the  depth  of  NMB  with
OF monitoring.
Khuenl-Brady et  al.24 compared  neostigmine  with  sug-
mmadex in  a  randomized  multicentre  study  where  it  was
pplied to  reverse  the  medium  NMB  obtained  with  rocuro-
ium or  vecuronium  in  adults.  In  the  rocuronium  group,  the
uration from  sugammadex  or  neostigmine  administration
o reach  0.90  TOF  ratio  was  found  to  be  1.4  min  with  sugam-
adex and  17.6  min  with  neostigmine.  In  a  study  of  Blobnerhe 0.90  TOF  ratio  in  5  min  and  98%  of  the  patients  in  the
ugammadex group  reached  the  0.90  TOF  ratio  in  5  min.  We






































































20.  Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-04  
.90  TOF  ratio,  which  was  0.46  min  in  the  sugammadex  group
nd 1.96  min  in  the  neostigmine  group.
Della Rocca  et  al.26 reported  that  the  pharmacokinetic
ffects of  sugammadex  were  the  same  in  children  and
dults. Plaud  et  al.  compared  the  efﬁciency  and  safety  of
ugammadex in  infants  (28  days--23  months  old),  in  chil-
ren (2--11  years  old),  in  adolescents  (12--17  years  of  age),
nd in  adults  (18--65  years  of  age).  Doses  of  0.5,  1,  2,
 mg  kg−1 sugammadex  and  a  placebo  were  compared  in
atients after  NMB  achieved  with  rocuronium.  The  different
ge groups  were  evaluated  for  possible  side  effects,  time  to
each TOF  0.90  ratio,  electrocardiographic  variations,  sug-
mmadex and  rocuronium  plasma  levels.  When  ≥2  mg  kg−1
ugammadex  was  applied,  the  time  to  reach  TOF  0.90  was
igniﬁcantly shorter  than  in  the  placebo  group.  In  infants,
hildren, adolescents  and  adults  NMB  reversal  time  with
ugammadex, and  sugammadex-rocuronium  concentrations
ere similar.  Reappearance  of  block,  insufﬁcient  reversal
f NMB  and  QT  lengthening  were  not  observed  in  any  of
he groups.  This  was  the  only  prior  study  which  evaluated
he efﬁciency  of  sugammadex  in  children.9 In  our  study,
ugammadex 2  mg  kg−1 was  administered  to  2--12-year-old
ediatric patients.  In  the  study  performed  by  Plaud  et  al.,
he time  to  reach  0.90  TOF  ratio  was  found  to  be  1.2  min  in
oth pediatric  and  adult  patients  who  were  given  2  mg  kg−1
ugammadex.  However,  the  number  of  patients  included
n that  study  is  insufﬁcient.  Therefore,  it  is  necessary  to
onduct a  comprehensive  study  involving  large  infant  and
ediatric patient  groups.
In  our  study  the  extubation  times  were  signiﬁcantly
igher in  the  neostigmine  group  compared  to  the  sugam-
adex group.  TOF  ratios  of  the  neostigmine  group  in  the
rocess of  NMB  reversal  were  conﬁrmed  to  be  higher  than
hose of  the  sugammadex  group.  Despite  that  difference,
he TOF  ratios  in  the  neostigmine  group  were  signiﬁcantly
ower at  the  extubation  than  in  the  sugammadex  group.  The
xtubation TOF  mean  was  76.95  ±  31.0  for  the  neostigmine
roup and  96.35  ±  21.34  for  the  sugammadex  group.  Time
o reach  TOF  rates  over  0.90  was  found  to  be  prolonged  as
our times  in  the  neostigmine  group  compared  to  the  sugam-
adex group.  Results  in  our  study  were  similar  to  previous
tudies.18,19
No  signiﬁcant  effects  on  heart  rate  were  recorded
ith sugammadex;  however,  neostigmine  caused  signiﬁ-
ant increases  in  the  mean  heart  rate  in  the  second,  ﬁfth
nd tenth  minutes  after  administration.18 In  our  study,  we
id not  conduct  a  hemodynamic  comparison.  However,  the
otential side  effects  of  bradycardia,  tachycardia,  hypoten-
ion and  hypertension  were  observed  in  neither  of  the
roups.
onclusion
ower  abdominal  and  urogenital  surgery  make  up  a  large
roportion of  the  pediatric  surgery  outpatient  operations.
his brings  NMB  reversal  and  PORC  avoidance  to  great  impor-
ance, especially  when  dealing  with  younger  children.  Our
tudy indicated  that  the  administration  of  sugammadex  for
he reversal  of  rocuronium  induced  NMB  is  making  faster
nd also  safer  NMB  reversal  possible,  when  compared  with
 traditional  drug,  as  neostigmine  is.T.  Kara  et  al.
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